6505--Insulin (VA-25-00026482)

The Department of Veterans Affairs National Acquisition Center is seeking proposals for human insulin products to be distributed through VA and DoD Pharmaceutical Prime Vendor (PPV) programs. The solicitation is divided into three distinct groups: Group 1 covers human insulin products including 70/30, N, and R in pen and vial forms; Group 2 focuses on rapid-acting analog insulins; and Group 3 covers long-acting insulin products. Contractors must provide unique 11-digit NDC numbers specific to their company for each product offered and include a 0.5% Cost Recovery Fee in their pricing. The evaluation will be conducted on a lowest-price technically acceptable basis, with the potential for separate awards for each group. The original proposal deadline was March 11, 2025, at 2:30 PM CT, but has since been extended to March 14, 2025, at 2:30 PM CDT.

The contract will serve multiple federal entities, including VA facilities, Department of Defense (for Groups 1 and 2), Indian Health Service, Bureau of Prisons, Federal Health Care Center, and certain State Veterans Homes. The procurement is structured with a base year and four one-year option periods, with implementation to begin after award. Products will be distributed through approximately 56 total distribution centers (31 VA PPV and 25 DoD PPV). To be considered for award, offerors must propose on all line items within a group for both base and option years. While no specific set-aside is noted for this procurement, the contract falls under the NAICS category 325412 for Pharmaceutical Preparation Manufacturing and PSC category 6505 for Drugs and Biologicals, indicating a specialized pharmaceutical procurement opportunity.